CD19 and neoplasm: Furthermore, to test if the IFNγ neutralization interferes with the kinetics of target killing in short (few hours) and long timeframes (up to 64 h), the anti-lymphoma activity of CAR.CD19-T cells against Daudi tumor cells was analyzed through a real-time, quantitative, live-cell imaging system that allows the visualization and quantification of live GFP+ cells over time.